Science to Systems Grant Program

Annabelle M. Belcher, PhD
Assistant Professor, Department of Psychiatry
Division of Addiction Research and Treatment
University of Maryland School of Medicine (UMSOM)

Co-Investigators:
Bethany DiPaula, PharmD
Natalie Spicyn, MD

This project focuses on reducing stigma and expanding access to telemedicine-based medication for opioid use disorder (Tele-MOUD) in rural jail settings. The intersection of opioid use disorder (OUD) and incarceration. For the past decade or more, the US has remained mired in an opioid crisis, a public health issue that is particularly salient for people with criminolegal involvement (CLI). Estimates suggest that up to 36% of people with OUD cycle through the correctional system each year, and that more broadly, 15% of people who are incarcerated have an OUD. Tragically, these individuals also face a significantly higher risk of drug-related overdose death, with as much as 129 times greater risk than the general public of overdose death in the weeks following community re-entry. Closer to home, Maryland data support these findings; a state-commissioned report found that the risk of overdose was 8.2 times greater in the first week after release from Maryland jails, compared to the period of 90-365 days following release. The reasons for this heightened risk are many, but chiefly, without MOUD protocols in place, jails and prisons use withdrawal/detoxification procedures that lower a person's tolerance, leading to a higher risk of overdose upon release.

Peter Manza, PhD
Assistant Professor, Kahlert Institute for Addiction Medicine
Department of Psychiatry

Co-Investigator:
Annabelle M. Belcher, PhD
Assistant Professor, Division of Addiction Research and Treatment
Department of Psychiatry

Study Physician:
Aaron D. Greenblatt, MD
Assistant Professor, Division of Addiction Research and Treatment
Department of Psychiatry

This project explores the potential of intramuscular ketamine as a novel treatment approach for opioid use disorder.  Opioid use disorder (OUD) remains a critical public health crisis nationally and locally. Baltimore City accounted for more than 38% of Maryland’s overdose deaths in 2022. Between 2017 and 2021, opioid related deaths in Baltimore city rose by approximately 45.9%, signaling an urgent need for scalable, evidence-based treatments. Methadone is a first-line pharmacological treatment for OUD that reliably reduces drug use and improves both mental and physical health. However, individuals must initially undergo a slow dose-titration process that can take several weeks before reaching an effective therapeutic level. Throughout this period, people commonly experience distressing withdrawal symptoms, especially craving, negative affect, insomnia, and chronic pain, which impair decision making and motivate drug reuse to alleviate these aversive states. As such, most dropouts occur within the first three months of treatment. This underscores the urgent need for adjunctive interventions that rapidly reduce OUD symptom severity during the vulnerable initiation phase of methadone therapy.

Donna Calu (Gogerdchi), PhD
Department of Neurobiology

Sarah Kattakuzhy, MD
Department of Medicine

This project aims to bridge laboratory and clinical research to better understand and treat polysubstance use disorder.  Problem and Significance: Individuals seeking treatment for Opioid Use Disorder (OUD) are rarely using opioids alone. Instead, they use two or more drugs of different classes (sedatives, psychostimulants, etc.), either through contamination of the drug supply or intentional co-use. Polysubstance use is considered the fourth wave of the opioid crisis and is characterized by a dynamically changing profile of co-used substances that varies by geographical region1. With Maryland once again at the center of the national opioid crisis, it is imperative that we establish translational pipelines that flexibly adjust to the changing landscape of the polysubstance opioid crisis. This requires collaboration between clinicians, who are working with patient populations to identify polysubstance misuse patterns, and pre-clinical scientists, who can disentangle the impact of each substance on opioid consumption, craving, withdrawal and relapse. This will lead to bidirectional translation in which pre-clinical findings inform streamlined clinical data surveillance and clinical survey data inform controlled preclinical testing to identify substances that enhance opioid craving, consumption, withdrawal and relapse.

Principal Investigator:
Doris Addo-Glover, PhD, MSN, RN
Assistant Professor
University of Maryland School of Nursing (UMSON)
Universities at Shady Grove, Rockville, Maryland

Co-Principal Investigator:
Courtney Townsel, MD, MSc
Assistant Professor
University of Maryland School of Medicine

This project examines innovative, supportive interventions aimed at preventing relapse among postpartum women with opioid use disorder.  Problem and Significance The postpartum period represents a critical time when women diagnosed with opioid use disorder (OUD) are more vulnerable to relapse and overdose deaths. Relapse rates exceed 90%, particularly 6-12 months following childbirth, and overdose deaths are a leading cause of death in postpartum parenting women (PPW) with OUD (PPW-OUD). From 2018-2021, overdose death ratios among pregnant and postpartumwomen,10-44 years old more than doubled per 100,000 mothers, in the United States. State records show fentanyl and particularly heroin contributed to the majority of maternal overdose deaths, among birthing women, reflecting the need for a different treatment approach to reduce relapse rates. Any substance use during pregnancy is discouraged due to the risks of poor maternal birth and infant outcomes (i.e., likelihood of emergent cesarian delivery, preterm and low birth weight infants).

Principal Investigator:
Jay Unick, PhD
Professor, School of Social Work

Collaborating Units:
University of Maryland School of Social Work
University of Maryland School of Nursing

This collaborative project evaluates recovery housing models to identify best practices and improvelong-term outcomes for individuals in recovery.  Recovery residences (RR) are essential components of the continuum of care for individuals recovering from substance use disorders. These residences bridge the substance use treatment system (e.g. detoxification, inpatient, and residential treatment) and sustained community recovery. RR at a minimum offer peer-based recovery support and a safe drug and alcohol-free living environment for individuals but may also offer a mix of services including formal linkages to outpatient substance use treatment programs and connections to recovery services. The National Alliance for Recovery Residences (NARR) framework classifies RR into four 
levels based on staffing and support intensity. Level 1 residences are peer run with no paid staff and minimal formal linkages to care. Level 2 residences are monitored programs with a paid house manager and some connections to clinical services. Level 3 residences are supervised programs with more structured recovery support services. Level 4 residences are typically linked to treatment providers. Existing evidence suggests that RR are a cost-effective intervention that increases abstinence, reduces relapse, improves treatment retention, enhances social outcomes such as employment and income, and lowers arrest rates. The objective of this study is to survey existing RR in Maryland to understand staffing structures, including the integration of peers, identify the services offered, and identify barriers and challenges to expanding recovery services. To achieve this, we will use the Maryland Certification of Recovery Residences (MCORR) list to draw a geographically diverse sample of 60 certified RR operators. The sample will be stratified by region (Capital, Central Maryland, Eastern Shore, Southern Maryland, and Western Maryland. Survey development, recruitment, interviewing, data analysis, and reporting survey will be done in collaboration with our Community Advisory Council PARTNER (Peer Action Research – Transformative Networks Enhancing Recovery). PARTNER is a long-standing collaborative group of peers with lived experience, RR agency leaders, trainers, advocates, and academic partners.

Edward C. Traver, M.D., Assistant Professor, School of Medicine, Principal Investigator

In the past decade, the opioid epidemic in the United States has led to profound and widespread suffering and death. For each of the past 3 years, over 100,000 Americans have died from opioid overdoses, (1) leading to a historic decrease in life expectancy that is unprecedented in modern times. The evolving regulatory and enforcement policies have led to many shifts in the source of illicit opioids, from diverted prescription opioids, to heroin, and now to illicit fentanyl and fentanyl derivatives.(2) Since the early 2000s, the non-opioid veterinary sedative xylazine has spread throughout the illicit fentanyl supply in the United States, with a notable epicenter in Baltimore and Philadelphia, where it is found in the vast majority of illicit opioids.(3,4) Xylazine has been suspected of contributing to high rates of fatal overdose, yet other evidence shows xylazine causes sedation without dangerous respiratory depression, perhaps reducing the risk of fatal overdose.(5) Many people who are exposed to xylazine also develop significant skin wounds, typically in the arms and legs, which can lead to severe infections and limb amputation.(6) As with overdose, evidence for a causal role for xylazine in the formation of these wounds is limited and conflicting. Better data is urgently needed to clarify the relationship between xylazine, overdose, and wounds, but investigations are hampered by insufficient xylazine testing. Inexpensive, rapid, and easy to use xylazine test strips (XTS) are available for people who use drugs (PWUD) to check their drugs for xylazine prior to use, but their use is limited by pressures to consume drugs quickly (such as to stave off withdrawal and avoid arrest). Even in ideal circumstances, fentanyl test strips (which are more widely deployed and studied) are used extremely rarely. Additional methods are needed to assess xylazine exposure among PWUD to confirm xylazine exposure, measure xylazine prevalence trends, and validate associations with overdose and wounds. It is unknown if XTS can be used to test for xylazine in the urine of PWUD. To answer these questions, we propose Xylazine Exposure among Baltimore Residents with Addiction (XEBRA) study, a prospective cohort of PWUD in two Baltimore harm-reduction and addiction programs to assess xylazine exposure and health risks.

Natalie Spicyn, MD, Assistant Professor, School of Medicine, Co-Principal Investigator

Noah Triplett, M.D., Assistant Research Professor, School of Medicine, Co-Principal Investigator

Cindy Schaeffer, M.D., Associate Professor, School of Medicine, Co-Principal Investigator

Adolescent substance use is a major public health concern. Adolescence is a critical developmental period, marked by major cognitive, physical, and social change.  Adolescence is also a period of increased risk-taking and increased risk, including for initiating substance use and developing a substance use disorder. Adolescence is the most common stage when individuals first begin using substances. Substance use in adolescence is associated with a variety of short-term risks, including motor vehicle crashes, increased prevalence of sexually transmitted infections, and higher rates of non-accidental injury. Adolescent substance use is also associated with great societal and healthcare costs as well as increased risk of developing 
substance use disorder (SUD) and other poor health outcomes later in life. 
Rural adolescents are uniquely and disproportionately impacted by substance use. 
Adolescents in rural areas drink alcohol at higher rates and are more likely to engage in high-risk 
behaviors than their urban peers, like extreme binge drinking (15+ drinks) or driving under the influence.
Rural adolescents also misuse opioids at higher levels than urban adolescents.
Understanding the interplay between the rural context and adolescent substance use and 
intervention is critical. Theoretical traditions in the fields of human development and 
psychopathology have long acknowledged the impact of social and environmental factors on 
human behavior,11,12 and research have commonly linked community, school, and social 
influences to adolescent substance use.  However, mixed-method research that blends 
qualitative data from rural communities with quantitative measures, such as those of social 
determinants of health, is needed to better understand how rural environments may confer greater 
risks and protection against substance use problems. This is critical to developing effective 
intervention strategies and improving wellbeing and decreasing substance use across the lifespan.

James Jang, PhD, UMB School of Social Work, Principal Investigator

Jennifer Lowther, MSW, Program Director, Co-Principal Investigator

A 2024 report published by the Substance Abuse and Mental Health Services Administration (SAMHSA), indicated that substance use disorders (SUDs) are on the rise, and that 48.7 million people over the age of 12 in the U.S. had a Substance Use Disorder (SUD) in the past year [1]. While there is limited data available regarding the prevalence of SUDs among parents, a 2019 study found that there may be 4.8 million American adults living with children who were experiencing a SUD [2]. Despite the large number of families that could benefit from interventions, there are limited evidence-based interventions available to address SUDs within the family context. 

Research suggests that the earliest years of a child's life (ages 0 to 3) are the most critical for cognitive, social, and emotional development [3], yet families in marginalized communities often lack access to the supportive resources necessary to foster healthy growth during this crucial period [4]. Structural inequities, including intergenerational trauma, substance use disorders (SUDs), economic instability, and systemic racial discrimination exacerbate disparities in early childhood development [5]. For children between the ages 0-3, the research suggests early childhood neglect, unstable caregiving environments, and lack of access to enriching early learning opportunities can have long-term consequences, including poor school readiness, developmental delays, and behavioral challenges [6]

Baltimore City has a high concentration of children living in at-risk families, many of whom face systemic barriers that impede their developmental, emotional, and social well-being [7]. While early intervention is critical to breaking cycles of poverty and adversity [8], there are limited evidence- based programs in Baltimore City that focus specifically on families with children ages 0-3. Without early engagement, children from disadvantaged and under resourced communities enter kindergarten already behind their peers, contributing to an achievement gap that persists throughout their educational careers [9]. To disrupt intergenerational SUDs a focused approach that prioritizes outreach and intervention for families with young children is critical in mitigating the long-term effects of early childhood adversity due to SUDs. 

Celebrating Families! (CF!) is a model that has been developed to support families experiencing SUDs through an intergenerational, community-based intervention. Early studies of this model have yielded statistically significant results indicating that parents increase their social, emotional, and coping and health promotion skills, and decreases 
the risk of addiction. These studies also show statistically significant improvements in family communication skills and cohesion and that children showed a decrease in covert aggression and attention/concentration problems. Participating families were seen to have a significant reduction in time to family reunification [10]. . More evaluation of this program is needed to understand the scope of its impacts. By implementing and evaluating CF! we aim to determine its impact, which will contribute to the evidence base. If the model is shown to be effective it could be adopted in other locations thus expanding the available interventions for families affected by SUDs. Additionally, this initiative will serve as an intervention for families affected by substance use disorders (SUDs) and a groundbreaking training opportunity for future practitioners and community health workers. 

Titilola Akintola-Mala PhD, Research Staff Scientist, School of Nursing, Principal Investigator

Luana Colloca, PhD, Professor, School of Social Nursing, Principal Investigator

Opioid Use Disorder (OUD) continues to be a major public health crisis in the United 
States affecting more than 2 million people in the United States (Azadfard 2023). 
Despite this, recent estimates from the National Institute on Drug Abuse (NIDA) show 
that only 1 in 5 people receive the needed treatment (Jones 2023). OUD
disproportionately affects underserved urban populations with profound implications for 
individuals, families, communities and cities (Dydyk 2023; NJOTF 2019). Baltimore
specifically, has seen a rise in opioid-related overdose deaths, recording more than 44% 
of Maryland’s overdose deaths in 2024 (ORF2025). With rates above the national 
average, the limited available resources are often limited strained, contributing to 
Baltimore being underserved (Gondré-Lewis 2023).

The standard of care for OUD is FDA approved medications for OUD (MOUD) 
(including Methadone, Buprenorphine, Suboxone) and psychotherapeutic interventions. 
Psychosocial interventions are often highly encouraged alongside MOUD to modify 
dysfunctional cognitive and behavioral patterns that are intrinsic to OUD (Bruneau, 
2018; Rice 2020) including craving—a central component of OUD. While a number of
psychotherapeutic interventions exist, they see limited success due to various issues 
including limited access (often related to transportation issues), lack of patient
engagement and motivation and stigma (Bremmer 2023, Jones 2023). Previous metaanalyses show that up to half (37%-50%) of people in traditional psychosocial OUD treatments drop out in less than 3 months (Dutra 2008; Lappan 2020). Due to these barriers, relapse rates remain high, presenting a compelling need to develop innovative and evidence-based psychotherapeutic interventions that can enhance treatment
engagement and retention, reduce relapse and improve OUD outcomes.

Megan Meyer MSW, PhD, School of Social Work – Principle Investigator
Andrew Coop, PhD, School of Pharmacy – Co-Investigator
Fernando Wagner, PhD, School of Social Work – Co-Investigator
Seante Hatcher, MSW, School of Social Work – Co-Investigator
Lynn Marie Bullock, DNP, RN, NEA-BC, School of Nursing – Co-Investigator

A growing body of research on the potential of psychedelic-assisted therapies (PAT) to 
treat a variety of mental health conditions, including substance abuse and addiction, has 
coincided with rising mental health and substance abuse rates in recent years and the drug 
decriminalization movement, fueling what’s being described as the “psychedelic renaissance”
(Brain Futures, 2022). It is well-known, for instance, that substance use disorders (SUDs) and 
death rates due to substance use have risen in the last decade, especially during the pandemic, 
with over 106,600 deaths due to drug overdose in 2021 - the highest on record (Panchal et al., 
2023). Rates of psychedelic use are no exception to rising use rates, with an estimated 2% of the 
U.S. population using hallucinogens in 2018 (Substance Abuse and Mental Health Services 
Administration, 2019), an increase of 56% since 2015 (Yockey et al., 2020). Coinciding with 
escalation in drug abuse and overdose rates, however, is research evidence demonstrating the 
efficacy of PAT to treat addiction. A 2016 systematic review of 25 years of clinical trials 
summarized the anti-addictive effects of psychedelics, presenting evidence supporting the 
efficacy of LSD and psilocybin for treating alcohol, tobacco and heroin use disorders (dos Santos 
et al., 2016). A 2017 study of 44,000 illicit opioid users, from the National Survey on Drug Use 
and Health between 2008 and 2013, found psychedelic use was associated with a 40% reduced 
risk of opioid abuse and 27% reduced risk of dependence (Pisano et al., 2017). A 2019 survey of 
343 respondents with prior alcohol use disorder (AUD) and reporting cessation or reduction after 
the use of psychedelics in non-clinical settings found that 83% no longer met the AUD criteria 
following their psychedelic experience (Garcia-Romeu et al., 2019).

Paul Sacco, PhD, MSW, School of Social Work – Principal Investigator
Laura Ting, PhD, MA, School of Social Work – Principal Investigator

The purpose of this study is to foster a highly skilled and committed workforce, the proposed project aims to conduct pilot 
exploratory analysis with the goal of developing intervention components to prevent burnout and 
increase retention among early career behavioral health professionals. Using a sequential QUALqual design,
41 we will begin by gathering data from newly graduated social workers and nurses
(>6 months & <2 years) working in behavioral health settings and then conduct interviews with 
clinical supervisors and program directors in behavioral health settings. In the interviews with new 
clinicians, we will explore their personal strategies for preventing burnout, their future intentions 
with respect to leaving their jobs, and the support they are currently receiving at work. We will 
also ask them to reflect on and discuss various potential modalities for helping to offset burnout 
and promote retention including compensation, training, and clinical supervision. 
Using insights gathered from the new clinicians, we will then conduct interviews with provider 
leadership. During these interviews, we will share information about main themes from the new 
clinicians, with an emphasis on gathering leaderships’ feedback about the feasibility and scalability
of different potential interventions where they work. We will also explore their ideas for retaining 
staff and preventing burnout among early career behavioral health providers. Our specific aims 
are:
Specific Aim 1: Examine how early career nurses and social workers in behavioral health settings
remain engaged with their work and avoid occupational burnout and explore the acceptability of 
potential individual level approaches.
Specific Aim 2: Explore the feasibility and scalability of retention intervention components for 
implementation among new clinicians working in behavioral health settings.
Our aims are closely aligned with The Center for Addiction Research, Education, and Service 
(CARES) mission, Core 1: Workforce development and community-based training and technical 
assistance) of the CARES mission which states that faculty will “Conduct needs assessment by 
discipline to identify primary barriers to addiction-related workforce participation and retention 
among behavioral health professionals” (see https://www.umaryland.edu/cares/). The proposed 
research also reflects the goals of a NIDA Notice of Special Interest (NOT-DA-23-008). In this 
NOSI, it states, “There are numerous individual-, organizational-, and system-level challenges to 
recruiting, training, and retaining behavioral health professionals. Unfortunately, little research has 
been conducted to develop and evaluate strategies to addressing these challenges.”

Max Spaderna, MD, School of Social Medicine – Principal Investigator
Sarah Kattakuzhy, MD, MPH, School of Medicine – Co-Investigator
Habib Omari, PhD, School of Medicine – Co-Investigator
Elana Rosenthal, MD, School of Social Medicine – Co-Investigator

This study will look at barriers and facilitators associated with linkage to, delayed 
linkage to, and retention in psychiatric care. To answer these questions, we will use data from 
the Long-term Outcomes of Opioid-using Persons (LOOP) study, a two-year, prospective, 
natural-history cohort of 200 individuals designed to characterize opioid use. The LOOP study is 
fully enrolled and anticipated to complete data collection in August 2023. Participants were 
eligible for LOOP if they were older than 18 years old and met criteria for OUD within the past 
three years. Every six months, LOOP participants complete surveys regarding their 
demographics, substance use outcomes, psychiatric symptoms, and quality of life outcomes. 
Patients identified as needing a referral to a psychiatrist can be linked either to a psychiatrist in 
the community or a psychiatrist associated with LOOP that can treat patients through
telemedicine visits.
AIM 1: Identify factors associated with linkage to psychiatric care in patients with OUD referred 
for psychiatric treatment.
• Hypothesis 1a: Successful linkage will be associated with lower OUD scores, more 
severe psychiatric illness as rated by screening tools, and telemedicine mode of 
psychiatric services (vs. in person)
o Endpoint: Linkage to care, defined as attendance of at least one visit with the 
LOOP psychiatrist
• Hypothesis 1b: Time to linkage to care, defined as number of days from referral to first
intake appointment, will be associated with OUD scores and mode of psychiatric services 
o Endpoint: Time to linkage to psychiatric care with the LOOP psychiatrist
Aim 1 Approach: Utilizing existing data from LOOP, we will identify patients referred to the 
LOOP psychiatrist at any time point and assess for linkage and time to linkage to psychiatric 
care. Frequencies of demographics, substance use outcomes, severity of psychiatric illness, 
model of care visit (in person vs. telemedicine) and quality of life metrics will be compared 
based on linkage (Aim 1a) and time to linkage (Aim 1b) to care. Multivariable logistic regression 
models will be used to compute adjusted odds ratios and 95% confidence intervals for 
associations between multiple factors and linkage to psychiatric care. Poisson regression models 
will be used to compute incidence rates of delayed linkage in care. Multivariable Cox 
proportional-hazards models will be used to determine factors associated with delayed linkage to 
care. Patients will accumulate person-time from when they are referred to psychiatric care to 
when they attend their first visit with the LOOP psychiatrist.
AIM 2: Identify factors associated with retention in psychiatric care for patients with OUD. 
• Hypothesis 2: Retention in psychiatric care with the LOOP psychiatrist for patients with 
OUD will be associated with lower OUD scores and telemedicine mode of psychiatric 
services (vs. telemedicine)
o Endpoint: Retention in care, defined as remaining in psychiatric care with the 
LOOP psychiatrist for 6 months after linkage
Aim 2 Approach: Utilizing LOOP data, we will compare patients with OUD based on their 
retention in psychiatric care by frequencies of demographics, substance use, severity of 
psychiatric illness as rated by screening tools, model of care visit (in person vs. telemedicine), 
and quality of life metrics. Multivariable log-binomial regression models will be used to compute 
adjusted risk ratios and 95% confidence intervals for associations between multiple factors and 
retention in psychiatric care.
AIM 3: Understand barriers and facilitators to linkage to and retention in psychiatric care for 
patients with OUD. 

Nalini Negi, Ph.D., MSW, Associate Professor, University of Maryland School of Social Work, Principal Investigator
Wendy Camelo Castillo, MD MSc Ph.D., Assistant Professor, University of Maryland School of Pharmacy, Co-Principal Investigator
Fernando Wagner, Sc.D., MPH, Professor, University of Maryland School of Social Work, Co-Principal Investigator

Project Description: Latinos who are mostly foreign-born and monolingual are among the fastest-growing groups in Baltimore. With CARES funding, we will gather important Phase I pilot data for a NIH R01 proposal to implement a larger research program to build an integrated system of care for under-insured or uninsurable substance-using Latino im/migrants (LM). Using Community Based Participatory Research (CBPR) principles, six focus groups with LM and six with behavioral health specialists (BHS) will be conducted to elucidate barriers and facilitators to SUD services in Baltimore. Next, a Community Advisory Board (CAB) consisting of LM and BHS will co-initiate the building of a “system of care” approach for substance-using underinsured, and uninsurable Latino immigrants in Baltimore. This application represents an important step toward decreasing health disparities among an extremely vulnerable and underserved population, Latino immigrants. 

Brook W. Kearley, Ph.D. Research Assistant Professor, University of Maryland School of Social Work, Principal Investigator 
Annabelle M. Belcher, Ph.D., Assistant Professor, University of Maryland School of Medicine, Co-Investigator 
Alexandra Wimberly, Ph.D. Assistant Professor, University of Maryland School of Social Work, Co-Investigator

Project Description: This qualitative study will assess potential barriers to staff acceptability of medication for opioid use disorder (MOUD) programs in detention centers.  Study aims include A1a. Assess staff acceptance of soon-to-be-implemented MOUD programs at four geographically diverse Maryland jails; A1b: Assess for types of stigmas held by these staff, including (1) perceptions of MOUD efficacy, (2) attitudes towards MOUD, and (3) stigma against people who use opioids (PWUO); A2. Assess any differences in perceptions and attitudes towards MOUD and PWUO between various levels of staff in these detention center settings (leadership, line officer, health/medical, discharge coordination staff) across the sites; and A3. Assess the feasibility of a staff-tailored training intervention designed to address barriers to MOUD acceptability. 

Bethany DiPaula, Pharm.D., BCPP, FASHP, Professor, University of Maryland School of Pharmacy, Principal Investigator 
Catherine Cooke, PharmD, MS, BCPS, PAHM, Research Associate Professor, University of Maryland School of Pharmacy, Principal Investigator

Project Description: Inadequate access to medications for opioid use disorder (OUD) contributes to undertreatment and has been exacerbated by the COVID pandemic. Variable pharmacy access to buprenorphine has been raised as a local and national issue, yet data on the extent of this problem, contributing factors, and solutions are limited and conflicting. This project will assess the availability of buprenorphine/naloxone in Maryland community pharmacies and real-world obstacles that pharmacists face when stocking and dispensing this medication for the treatment of OUD. Based on the findings, the researchers will propose targeted strategies to address the obstacles. The goal is to improve treatment access and care for individuals with OUD.

Max Spaderna, MD, Assistant Professor, University of Maryland School of Medicine, Principal Investigator 
Charles Callahan, DO, Adjunct Professor, University of Maryland School of Medicine, Co-Principal Investigator 
Aaron D. Greenblatt, MD, Assistant Professor, University of Maryland School Medicine, Co-Principal Investigator 
Samuel B. Little, Ph.D., Clinical Associate Professor, University of Maryland School of Social Work, Co-Principal Investigator 

Project Description: Providing permanent housing benefits homeless individuals with opioid use disorder, but this is often difficult to provide, The Social Work Assistance and Stipends for Housing (SASH) study will give six months of housing stipends that can be used for a broad range of temporary housing options to homeless individuals receiving methadone for opioid use disorder treatment. These stipends will be accompanied by 12 months of Social Work assistance aimed at finding permanent housing for the participants. The purpose of SASH is to determine whether these interventions will improve outcomes for housing, quality of life, opioid use disorder, and methadone treatment.

Michelle Tuten, Ph.D., MSW, Associate Professor, School of Social Work, Principal Investigator
Aaron Greenblat, MD, Assistant Professor, Scool of Medicine, Co-Principal Investigator 
Eric Weintraub, MD, Associate Professor, School of Medicine, Co-Principal Investigator

The proposed study represents phase I of a multi-phase research plan to develop a smoking cessation intervention tailored to the specific needs of a population enrolled in OUD treatment. Phase I consists of a survey study of the demographic characteristics and smoking behaviors of patients enrolled in OUD treatment at baseline, and an initial efficacy trial for N=20 participants randomly assigned to receive smoking cessation medications combined with contingency management (CM) for daily medication ingestion (Enhanced smoking cessation [ESC: n=10]) or usual care (UC: n=10). These data will help us determine the population’s level of interest in smoking cessation intervention and provide initial data on whether enhanced care shows promise as a smoking reduction intervention. 

Specific Aims: 
AIM 1. To assess the demographic and smoking behaviors of N=50 patients enrolled in OUD treatment at baseline.  
AIM 2a. To compare participants randomly assigned to receive ESC or UC on demographic and smoking behaviors at baseline and 1, 3, and 6 months post-treatment (AIM 1).
AIM 2b. to assess the initial efficacy of ESC (n=10) relative to UC (n=10) on a proportion of the population who fill a prescription for smoking cessation medications, self-reported smoking quantity and frequency, self-reported NRT use, carbon monoxide levels, and substance use at 1, 3, and 6 months post-treatment enrollment.  
AIM 3. To assess the level of medication adherence (medication ingestion/scheduled observation sessions) for ESC participants.  

Annabelle M. Belcher, Ph.D., Assistant Professor, School of Medicine, Principal Investigator 
Todd Gould, MD, Professor, School of Medicine, Co-Principal Investigator
Eric Weintraub, MD, Associate Professor, School of Medicine, Co-Principal Investigator
Sarah Kattakuzhy, MD, Assistant professor, School of Medicine, Co-Principal Investigator

Methadone is a first-line, evidence-based treatment for opioid use disorder (OUD). Unfortunately, retention and adherence in methadone treatment is a major challenge. OUD patients frequently present with co-morbid depression (OUDCD), a risk factor for poor OUD treatment outcomes, overdose, and suicide. The last two decades have seen an exciting and transformational development in the treatment of depression – ketamine. As a safe, rapid-acting anti-depressant deliverable within the context of methadone maintenance treatment, ketamine could feasibly change the landscape of treatment for OUD patients with comorbid depression. This proposal seeks to evaluate implementation outcomes (feasibility and patient acceptance) as well as preliminary efficacy of ketamine on methadone treatment outcomes for OUD patients with comorbid depression and depressive symptoms presenting for methadone treatment.

Specific Aims:
SA1: Assess the feasibility and acceptance of a two-week regimen of sub- anesthetic antidepressant doses of ketamine as an adjunct to methadone in a racially diverse, low-income sample (n=6) of patients seeking treatment for opioid use disorder. 
SA2: Measure the impact of this ketamine dosing protocol on 1- and 3- month methadone maintenance treatment retention and depression.

Marik Moen, Ph.D., MPH, MSN, RN, Assistant Professor, School of Nursing, Principal Investigator
Max Spaderna, MD, Assistant Professor, School Of Medicine, Co-Principal Investigator 
Sarah Kattakuzhy, MD, Assistant Professor, School of Medicine, Co-Principal Investigator 
Aaron Greenblatt, MD, Assistant Professor, School of Medicine, Co-Principal Investigator

Substance use disorders (SUD) are among the greatest public health challenges facing the United States, resulting in millions of lives and billions of dollars lost. Improving research on SUD is necessary to address the public health crisis of substance misuse and disorders. Further, we recognize that successful employment and treatment for persons with SUD can prevent death and illness, but social determinants of health (e.g., housing, income, transportation, education) are barriers to treatment. As programs and employers seek to address these health-related social needs (HRSN), they are missing the stakeholder (patient, staff, and employer) perspective on how assessing unmet needs is viewed, what social needs are most relevant, and what to do about them. If we fail to grasp the stakeholder preferences and values, we miss opportunities to address critical problems, appropriately allocate resources, or adapt care/interventions for improved outcomes. To address the need for improved SUD research and lack of patient-centered approaches to addressing health-related social needs, the PURPLE and PEARL projects are collaborating to implement the following projects.

Improving Patient and Provider Engagement in Addiction Research Through A Longitudinal Research Collaborative - PEARL 
PEARL’s main objective to improve substance use research and incorporate the lived experience of individuals with substance use in the research process through the creation of a collaborative research council comprised of patients, staff, and investigators who will evaluate and develop addiction research. PEARL will consist of two interventions, the Research Advisory Council (RAC) and the Research Advisory Forum (RAF). The RAC will be comprised of investigators, staff, and patients of the ATP, and will meet quarterly to discuss and provide feedback on current protocols and various aspects of research including recruitment and compensation of study participants, study operations, study risks and benefits, promotion of justice and cultural relevance, and new ideas for substance use research projects. The semi-annual RAF open meeting will be led by patient RAC members as a forum to solicit feedback on several topics including making research projects more valid and meaningful to patients, addressing gaps in care that may inform the development of new investigations, and allowing Principal Investigators (PIs) to disseminate their research findings directly to the affected population.

Promoting Understanding in social needs Research Projects by Listening and Engagement - PURPLE 
PURPLE’s main objective is to help establish the PEARL RAC and then engage RAC members in guiding a qualitative research study. The PURPLE study seeks to gain firsthand expertise about the preferred methods of assessing, documenting, and addressing HRSN from persons with substance use disorders, from direct-service staff, and employers of persons with SUD. PURPLE will engage the PATIENTS program from the School of Pharmacy to facilitate implementation of the 10-Step Patient Engagement Framework and work with faculty from the Schools of Nursing, Social Work, and Medicine and ATP partners to implement the study. All interventions will be held at the University of Maryland Addiction Treatment Program (ATP), a certified substance use treatment program that collocates medical care, wellness programs, and research.

The reference list is not included in the 5-page limit for the proposal.

Yes, faculty salaries are supported by SSG funding and should be included in the budget. Faculty requesting salary support should ensure that any salary support is approved by their respective school deans or department heads, as appropriate. 

There are no specified limits on the amount of salary support that can be requested.

"The proposal also should identify specific goals that will enhance the success of a full proposal as well as provide a specific targeted timeline by which these objectives can be reasonably achieved."

The SSG proposal should specify the team's plans to apply for external funding and how the SSG pilot funding will enhance the team's prospect of obtaining future funding.